Parabilis Medicines (PBLS) vs Tango Therapeutics (TNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tango Therapeutics is the larger company by market cap ($3.87 billion vs $3.57 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PBLS | TNGX |
|---|---|---|
| Share price | $28.91 | $22.95 |
| Market cap | $3.57B | $3.87B |
| 1-day change | +2.90% | +1.68% |
| YTD return | — | +154.74% |
| 1-year return | — | +226.63% |
| 5-year return | — | +60.87% |
| EPS (TTM) | $-9.51 | $-0.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $62.38M |
| Revenue growth (YoY) | — | +48.29% |
| Net income (latest FY) | — | $-101.59M |
| Operating margin | — | -178.39% |
| Net margin | — | -162.85% |
| 52-week high | $42.49 | $34.39 |
| 52-week low | $24.51 | $6.69 |
| Distance from 52-week high | -31.97% | -33.27% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +44.44% | +96.86% |
| Average volume | 690.91K | 2.65M |
| Shares outstanding | 121.95M | 168.61M |
| Employees | 145 | 137 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Parabilis Medicines
PBLS stock →Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
About Tango Therapeutics
TNGX stock →Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees
PBLS vs TNGX FAQ
Which is bigger, Parabilis Medicines or Tango Therapeutics?
Tango Therapeutics (TNGX) is larger, with a market capitalization of $3.87B compared with $3.57B for Parabilis Medicines (PBLS).
Are Parabilis Medicines and Tango Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.